|
1.
|
Welch HG, Schwartz LM and Woloshin S: Are
increasing 5-year survival rates evidence of success against
cancer? JAMA. 283:2975–2978. 2000.
|
|
2.
|
Bates SE and Longo DL: Use of serum tumor
markers in cancer diagnosis and management. Semin Oncol.
14:102–138. 1987.
|
|
3.
|
Kluger HM, Hoyt K, Bacchiocchi A, et al:
Plasma markers for identifying patients with metastatic melanoma.
Clin Cancer Res. 17:2417–2425. 2011.
|
|
4.
|
Cohn SL, Lincoln ST and Rosen ST: Present
status of serum tumor markers in diagnosis, prognosis, and
evaluation of therapy. Cancer Invest. 4:305–327. 1986.
|
|
5.
|
Virji MA, Mercer DW and Herberman RB:
Tumor markers in cancer diagnosis and prognosis. CA Cancer J Clin.
38:104–126. 1988.
|
|
6.
|
Maxwell P: Carcinoembryonic antigen: cell
adhesion molecule and useful diagnostic marker. Br J Biomed Sci.
56:209–214. 1999.
|
|
7.
|
Molina R, Filella X, Auge JM, et al: Tumor
markers (CEA, CA 125, CYFRA 21-1, SCC and NSE) in patients with
non-small cell lung cancer as an aid in histological diagnosis and
prognosis. Comparison with the main clinical and pathological
prognostic factors. Tumour Biol. 24:209–218. 2003.
|
|
8.
|
Hammarstrom S: The carcinoembryonic
antigen (CEA) family: structures, suggested functions and
expression in normal and malignant tissues. Semin Cancer Biol.
9:67–81. 1999.
|
|
9.
|
Tan E, Gouvas N, Nicholls RJ, et al:
Diagnostic precision of carcinoembryonic antigen in the detection
of recurrence of colorectal cancer. Surg Oncol. 18:15–24. 2009.
|
|
10.
|
Carney DN and Teeling M: Neuron-specific
enolase: how useful as a cancer marker? Eur J Cancer Clin Oncol.
24:825–828. 1988.
|
|
11.
|
Hatzakis KD, Froudarakis ME, Bouros D, et
al: Prognostic value of serum tumor markers in patients with lung
cancer. Respiration. 69:25–29. 2002.
|
|
12.
|
Cooper EH: Neuron-specific enolase. Int J
Biol Markers. 9:205–210. 1994.
|
|
13.
|
Saloustros E and Mavroudis D: Cytokeratin
19-positive circulating tumor cells in early breast cancer
prognosis. Future Oncol. 6:209–219. 2010.
|
|
14.
|
Uenishi T, Kubo S, Hirohashi K, et al:
Cytokeratin-19 fragments in serum (CYFRA 21-1) as a marker in
primary liver cancer. Br J Cancer. 88:1894–1899. 2003.
|
|
15.
|
Stieber P, Hasholzner U, Bodenmuller H, et
al: CYFRA 21-1: a new marker in lung cancer. Cancer. 72:707–713.
1993.
|
|
16.
|
Jain R, Fischer S, Serra S, et al: The use
of cytokeratin 19 (CK19) immunohistochemistry in lesions of the
pancreas, gastrointestinal tract, and liver. Appl Immunohistochem
Mol Morphol. 18:9–15. 2010.
|
|
17.
|
Groover JR and Rogers AI: Immunologic
tests for the detection of gastrointestinal cancers: status report
on carcinoembryonic antigen (CEA) and alpha-fetoprotein (AFP).
Southern Med J. 66:1218–1221. 1973.
|
|
18.
|
Chen L, Ho DW, Lee NP, et al: Enhanced
detection of early hepatocellular carcinoma by serum SELDI-TOF
proteomic signature combined with alpha-fetoprotein marker. Ann
Surg Oncol. 17:2518–2525. 2010.
|
|
19.
|
Kemer T, Ormen M, Kuralay F, et al:
Diagnostic usefulness of carbohydrate antigen-125 in cancerous and
noncancerous peritoneal effusions. Tohoku J Exp Med. 205:11–18.
2005.
|
|
20.
|
Oktay G, Guner G, Karlikaya C and Akkoclu
A: Serum levels of neuron-specific enolase, carbohydrate antigen
19-9 and carbohydrate antigen 125 in carcinoma of the lung. Biochem
Soc Trans. 23:211S1995.
|
|
21.
|
Yeh LS, Hung YC, Kao A, et al: Tissue
polypeptide specific antigen (TPS) and carbohydrate antigen 125
(CA-125) in the early prediction of recurrent ovarian cancer.
Anticancer Res. 22:3669–3671. 2002.
|
|
22.
|
Encabo G, Genolla J, Gefaell R and Ruibal
A: Serum carbohydrate antigen 19.9 in patients with digestive
cancers. Presse Med. 14:23041985.(In French).
|
|
23.
|
Halloran CM, Ghaneh P, Connor S, et al:
Carbohydrate antigen 19.9 accurately selects patients for
laparoscopic assessment to determine resectability of pancreatic
malignancy. Br J Surg. 95:453–459. 2008.
|
|
24.
|
van Ruth S, Hart AA, Bonfrer JM, et al:
Prognostic value of baseline and serial carcinoembryonic antigen
and carbohydrate antigen 19.9 measurements in patients with
pseudomyxoma peritonei treated with cytoreduction and hyperthermic
intraperitoneal chemotherapy. Ann Surg Oncol. 9:961–967. 2002.
|
|
25.
|
Torti SV and Torti FM: Iron and ferritin
in inflammation and cancer. Adv Inorg Biochem. 10:119–137.
1994.
|
|
26.
|
Richardson DR: Iron and neoplasia: serum
transferrin receptor and ferritin in prostate cancer. J Lab Clin
Med. 144:173–175. 2004.
|
|
27.
|
Slodkowska J, Szturmowicz M, Rudzinski P,
et al: Expression of CEA and trophoblastic cell markers by lung
carcinoma in association with histological characteristics and
serum marker levels. Eur J Cancer Prev. 7:51–60. 1998.
|
|
28.
|
Bergman B, Brezicka FT, Engstrom CP and
Larsson S: Clinical usefulness of serum assays of neuron-specific
enolase, carcinoembryonic antigen and CA-50 antigen in the
diagnosis of lung cancer. Eur J Cancer. 29A:198–202. 1993.
|
|
29.
|
Seemann MD, Seemann O, Dienemann H,
Schalhorn A, Prime G and Fink U: Diagnostic value of chest
radiography, computed tomography and tumour markers in the
differentiation of malignant from benign solitary pulmonary
lesions. Eur J Med Res. 4:313–327. 1999.
|
|
30.
|
Schneider J and Schulze G: Comparison of
tumor M2-pyruvate kinase (tumor M2-PK), carcinoembryonic antigen
(CEA), carbohydrate antigens CA 19-9 and CA 72-4 in the diagnosis
of gastrointestinal cancer. Anticancer Res. 23:5089–5093. 2003.
|
|
31.
|
Buccheri G, Torchio P and Ferrigno D:
Clinical equivalence of two cytokeratin markers in non-small cell
lung cancer: a study of tissue polypeptide antigen and cytokeratin
19 fragments. Chest. 124:622–632. 2003.
|
|
32.
|
Sung HJ and Cho JY: Biomarkers for the
lung cancer diagnosis and their advances in proteomics. BMB Rep.
41:615–625. 2008.
|
|
33.
|
Muraki M, Tohda Y, Iwanaga T, Uejima H,
Nagasaka Y and Nakajima S: Assessment of serum CYFRA 21-1 in lung
cancer. Cancer. 77:1274–1277. 1996.
|
|
34.
|
Gaspar MJ, Arribas I, Coca MC and
Diez-Alonso M: Prognostic value of carcinoembryonic antigen, CA
19-9 and CA 72-4 in gastric carcinoma. Tumour Biol. 22:318–322.
2001.
|
|
35.
|
Pujol JL, Boher JM, Grenier J, Quantin X,
Saffont L and Daures JP: Neuron-specific enolase (NSE) in the
surveillance of small cell cancers: an evaluation of the prognostic
information using Markov’s model. Rev Mal Respir. 15:519–525.
1998.(In French).
|
|
36.
|
Chou SF and Chen CY: Monoclonal and
polyclonal antibodies against human ferritin, a nonspecific tumor
marker. Hybridoma. 20:59–62. 2001.
|
|
37.
|
Aulbert E and Schmidt CG: Ferritin - a
tumor marker in myeloid leukemia. Cancer Detect Prev. 8:297–302.
1985.
|
|
38.
|
Dorner MH, Abel U, Fritze D, Manke HG and
Drings P: Serum ferritin in relation to the course of Hodgkin’s
disease. Cancer. 52:2308–2312. 1983.
|
|
39.
|
Bekci TT, Senol T and Maden E: The
efficacy of serum carcinoembryonic antigen (CEA), cancer antigen
125 (CA125), carbohydrate antigen 19-9 (CA19-9), carbohydrate
antigen 15-3 (CA15-3), alpha-fetoprotein (AFP) and human chorionic
gonadotropin (hCG) levels in determining the malignancy of solitary
pulmonary nodules. J Int Med Res. 37:438–445. 2009.
|
|
40.
|
Wu GP, Ba J, Zhao YJ and Wang EH:
Diagnostic value of CEA, CYFRA 21-1, NSE and CA 125 assay in serum
and pleural effusion of patients with lung cancer. Acta Cytol.
51:679–680. 2007.
|
|
41.
|
Donach M, Yu Y, Artioli G, et al: Combined
use of biomarkers for detection of ovarian cancer in high-risk
women. Tumour Biol. 31:209–215. 2010.
|
|
42.
|
Goldenberg DM, Sharkey RM and Primus FJ:
Immunocytochemical detection of carcinoembryonic antigen in
conventional histopathology specimens. Cancer. 42:1546–1553.
1978.
|
|
43.
|
Nunez GR, Ito C and Del Giglio A:
Increased serum CA-125 levels in patients with lung cancer post
thoracotomy. Southern Med J. 102:427–428. 2009.
|
|
44.
|
Beneduce L, Castaldi F, Marino M, et al:
Improvement of liver cancer detection with simultaneous assessment
of circulating levels of free alpha-fetoprotein (AFP) and AFP-IgM
complexes. Int J Biol Markers. 19:155–159. 2004.
|
|
45.
|
Beale G, Chattopadhyay D, Gray J, et al:
AFP, PIVKAII, GP3, SCCA-1 and follisatin as surveillance biomarkers
for hepatocellular cancer in non-alcoholic and alcoholic fatty
liver disease. BMC Cancer. 8:2002008.
|
